Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing discloses a specific transaction involving the GSK 401K plan:
- Date of Transaction: August 27, 2015
- Event: Increase in the notional allocation of GSK American Depositary Shares (ADSs) following the revaluation of the cash element of the notional investment.
- Price: $41.21 per ADS.
- Connected Person: Dr K Slaoui (Connected Person of Dr M Slaoui).
- Number of ADSs: 8.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Investor Verification Checklist
- Verify the total number of ADSs held by Dr K Slaoui and Dr M Slaoui following this transaction.
- Confirm the impact of the 401K plan revaluation on the broader employee share ownership structure.
- Review the current market price of GSK ADSs relative to the $41.21 transaction price noted in August 2015.